Lupin to Showcase Phase 1 Data for LNP3693 at ESMO Congress 2025 Lupin Limited is set to present critical Phase 1 data on LNP3693, a STING agonist, at the ESMO Congress 2025, highlighting potential advances in cancer treatment.

Lupin to Showcase Phase 1 Data for LNP3693 at ESMO Congress 2025 #India #Mumbai #Lupin_Limited #ESMO_Congress #LNP3693

Lupin to Showcase Phase 1 Findings of LNP3693 at ESMO 2025 Congress in Berlin Lupin Limited is set to present results from its Phase 1a trial of LNP3693, a STING agonist, at ESMO 2025, highlighting safety and efficacy for solid tumors.

Lupin to Showcase Phase 1 Findings of LNP3693 at ESMO 2025 Congress in Berlin #India #Mumbai #Lupin #LNP3693 #ESMO2025

Lupin to Present Phase I Data on LNP3693 at ESMO 2025 Congress Lupin Limited will showcase critical Phase I trial data for LNP3693, a STING agonist, at the ESMO 2025 Congress in Berlin, highlighting its potential in oncology.

Lupin to Present Phase I Data on LNP3693 at ESMO 2025 Congress #India #Mumbai #Lupin_Limited #ESMO_2025 #LNP3693

Lupin to Present Phase 1 Data of LNP3693 at ESMO Congress 2025 in Berlin Lupin Limited is set to present data from its Phase 1 trial of LNP3693, a STING agonist, at the ESMO 2025 Congress in Berlin, showcasing its potential in treating advanced solid tumors.

Lupin to Present Phase 1 Data of LNP3693 at ESMO Congress 2025 in Berlin #India #Mumbai #Lupin_Limited #ESMO_Congress #LNP3693

Lupin to Present Phase-1 Data on LNP3693 at ESMO Congress 2025 Lupin Limited announces the presentation of Phase-1 findings for LNP3693 at the ESMO Congress 2025, highlighting its potential in cancer treatment.

Lupin to Present Phase-1 Data on LNP3693 at ESMO Congress 2025 #India #Mumbai #Lupin_Limited #ESMO_Congress #LNP3693